

**Medicare Group Q.P.S.C.**

**INTERIM CONDENSED  
FINANCIAL STATEMENTS**

**FOR THE NINE-MONTH PERIOD ENDED  
30 SEPTEMBER 2024**


# Medicare Group Q.P.S.C.


## INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION

At 30 September 2024

		30 September 2024 (Unaudited) QR	31 December 2023 (Audited) QR
	Notes		
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property and equipment	4	1,035,007,788	1,048,647,205
Investment properties		26,270,000	26,270,000
Right-of-use assets		-	35,242,551
Investments at fair value through other comprehensive income		74,068,066	73,362,823
		<u>1,135,345,854</u>	<u>1,183,522,579</u>
<b>Current assets</b>			
Inventories		30,696,928	29,267,001
Accounts receivable and prepayments	5	130,578,241	120,881,846
Cash and bank balances	6	98,418,801	12,499,637
		<u>259,693,970</u>	<u>162,648,484</u>
Discontinued operations assets	9	160,465	-
		<u>259,854,435</u>	<u>162,648,484</u>
<b>Total assets</b>		<u>1,395,200,289</u>	<u>1,346,171,063</u>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital		281,441,000	281,441,000
Legal reserve		122,580,725	122,580,725
Fair value reserve		22,703,122	21,997,879
Revaluation reserve		521,813,753	523,897,804
Retained earnings		38,740,155	62,542,874
<b>Total equity</b>		<u>987,278,755</u>	<u>1,012,460,282</u>
<b>Non-current liabilities</b>			
Bank facilities		159,893,307	62,322,772
Lease liabilities		-	38,671,765
Employees' end of service benefits		86,239,390	81,220,694
		<u>246,132,697</u>	<u>182,215,231</u>
<b>Current liabilities</b>			
Accounts payable and accruals		126,628,503	122,159,540
Bank facilities		35,160,334	27,314,938
Lease liabilities		-	2,021,072
		<u>161,788,837</u>	<u>151,495,550</u>
<b>Total liabilities</b>		<u>407,921,534</u>	<u>333,710,781</u>
<b>Total equity and liabilities</b>		<u>1,395,200,289</u>	<u>1,346,171,063</u>

These interim condensed financial statements of the Company for the nine months ended 30 September 2024 were authorized for issue in accordance with a resolution of the Board of Directors on 23 October 2024.

  
Jamal Abdulla Al-Jamal  
Board Member

  
Khalid Mohammed Al-Emadi  
Chief Executive Officer

The attached notes 1 to 9 form part of these interim condensed financial statements.

Medicare Group Q.P.S.C.

INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER  
COMPREHENSIVE INCOME

For the nine-month period ended 30 September 2024

		<i>For the nine-month period ended 30 September</i>	
		<i>2024</i>	<i>2023</i>
		<i>(Unaudited)</i>	<i>(Unaudited)</i>
		<i>QR</i>	<i>QR</i>
	<i>Notes</i>		
<b>Continuing operations</b>			
Operating income		<b>382,432,434</b>	355,994,894
Operating costs	7	<b>(235,873,692)</b>	(223,633,840)
<b>Gross profit</b>		<b>146,558,742</b>	132,361,054
Income from deposits with Islamic Banks		<b>2,642,077</b>	459,239
Other income		<b>6,959,845</b>	5,523,791
General and administrative expenses	8	<b>(74,624,172)</b>	(68,989,398)
Depreciation of property and equipment		<b>(11,410,334)</b>	(10,390,064)
Finance costs		<b>-</b>	(18,531)
<b>Net profit for the period from continuing operations</b>		<b>70,126,158</b>	58,946,091
<b>Discontinued operations</b>			
Loss from discontinued operations	9	<b>(34,095,908)</b>	(8,557,000)
<b>Profit for the period</b>		<b>36,030,250</b>	50,389,091
<i>Other comprehensive income not to be reclassified to profit or loss in subsequent periods:</i>			
Net gain (loss) from investments at fair value through other comprehensive income		<b>705,243</b>	(2,909,175)
<b>Other comprehensive income (loss) for the period</b>		<b>705,243</b>	(2,909,175)
<b>Total comprehensive income for the period</b>		<b>36,735,493</b>	47,479,916
<b>Basic and diluted earnings per share (expressed in Qatari Riyals per share)</b>		<b>0.128</b>	0.179

The attached notes 1 to 9 form part of these interim condensed financial statements.

# Medicare Group Q.P.S.C.

## INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY

For the nine-month period ended 30 September 2024

	Share capital QR	Legal reserve QR	Fair value reserve QR	Revaluation reserve QR	Retained earnings QR	Total equity QR
Balance at 1 January 2023	281,441,000	116,010,669	18,365,451	549,025,726	75,356,136	1,040,198,982
Net profit for the period	-	-	-	-	50,389,091	50,389,091
Other comprehensive loss	-	-	(2,909,175)	-	-	(2,909,175)
Total comprehensive income	-	-	(2,909,175)	-	50,389,091	47,479,916
Dividends	-	-	-	-	(73,878,263)	(73,878,263)
Transfer of depreciation of revalued assets	-	-	-	(2,612,033)	2,612,033	-
Balance at 30 September 2023 (Unaudited)	281,441,000	116,010,669	15,456,276	546,413,693	54,478,997	1,013,800,635
Balance at 1 January 2024	281,441,000	122,580,725	21,997,879	523,897,804	62,542,874	1,012,460,282
Net profit for the period	-	-	-	-	36,030,250	36,030,250
Other comprehensive income	-	-	705,243	-	-	705,243
Total comprehensive income	-	-	705,243	-	36,030,250	36,735,493
Dividends	-	-	-	-	(61,917,020)	(61,917,020)
Transfer of depreciation of revalued assets	-	-	-	(2,084,051)	2,084,051	-
<b>Balance at 30 September 2024 (Unaudited)</b>	<b>281,441,000</b>	<b>122,580,725</b>	<b>22,703,122</b>	<b>521,813,753</b>	<b>38,740,155</b>	<b>987,278,755</b>

The attached notes 1 to 9 form part of these interim condensed financial statements.

# Medicare Group Q.P.S.C.

## INTERIM CONDENSED STATEMENT OF CASH FLOWS

For the nine-month period ended 30 September 2024

		<i>For the nine-month period ended 30 September</i>	
		<i>2024 (Unaudited) QR</i>	<i>2023 (Unaudited) QR</i>
	<i>Notes</i>		
<b>OPERATING ACTIVITIES</b>			
Net profit for the period from continuing activities		70,126,158	58,946,091
Net loss for the period from discontinued activities		(34,095,908)	(8,557,000)
<b>Profit for the period</b>		<b>36,030,250</b>	<b>50,389,091</b>
<i>Adjustments for:</i>			
Depreciation of property and equipment	4	19,453,373	19,357,302
Amortisation of right-of-use assets		783,168	1,762,128
Provision for obsolete and slow - moving inventories		194,490	-
Provision for employees' end of service benefits		9,073,472	6,758,320
Finance costs		535,258	1,278,413
Impairment loss on discontinued operations		36,242,212	-
Gain on termination of lease		(5,568,712)	-
Income from deposit with Islamic banks		(2,642,077)	(459,239)
Dividend income		(4,096,124)	(2,704,852)
Operating profit before working capital changes		90,005,310	76,381,163
<i>Working capital changes:</i>			
Inventories		(1,624,417)	(177,122)
Accounts receivable and prepayments		(4,121,958)	(3,349,737)
Accounts payable and accruals		6,390,626	(1,033,235)
Cash generated from operations		90,649,561	71,821,069
Employees' end of service benefits paid		(4,054,776)	(4,318,206)
Contribution paid to the social and sports fund		(1,642,514)	(1,979,120)
Finance costs paid		-	(18,531)
<b>Net cash flows from operating activities</b>		<b>84,952,271</b>	<b>65,505,212</b>
<b>INVESTING ACTIVITIES</b>			
Additions to property and equipment	4	(42,056,168)	(33,856,016)
Short term deposits		(78,000,000)	-
Advance payments towards capital projects		(4,139,942)	(4,598,605)
Profit received from deposit with Islamic banks		1,162,355	459,239
Dividend income received		4,096,124	2,704,852
<b>Net cash flows used in investing activities</b>		<b>(118,937,631)</b>	<b>(35,290,530)</b>
<b>FINANCING ACTIVITIES</b>			
Cash dividends paid		(62,196,169)	(72,652,871)
Additional bank facilities obtained during the period		200,000,000	44,936,779
Payment of lease liabilities		(1,200,000)	(2,100,000)
Repayment of bank facilities		(94,584,069)	(27,295,668)
<b>Net cash flows from / (used in) financing activities</b>		<b>42,019,762</b>	<b>(57,111,760)</b>
<b>NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS</b>		<b>8,034,402</b>	<b>(26,897,078)</b>
Cash and cash equivalents at the beginning of the period		12,499,637	42,150,235
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD</b>		<b>20,534,039</b>	<b>15,253,157</b>

The attached notes 1 to 9 form part of these interim condensed financial statements.

# Medicare Group Q.P.S.C.

## NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2024

### 1 REPORTING ENTITY

Medicare Group Q.P.S.C. (formerly known as “Al Ahli Specialized Hospital Company Q.S.C.”) is a Qatari Public Shareholding Company incorporated on 30 December 1996 under the Commercial Registration number 18895. The Company’s main activity is the operation of a specialized hospital and promoting medical services in the State of Qatar. The Company’s registered office address is at Ahmed Bin Ali Street, Wadi Al Sail, Doha, State of Qatar, P.O. Box 6401. The Company is listed on the Qatar Stock Exchange.

The Company provides medical services through Al Ahli Hospital located in Wadi Al Sail. The Company also operates a medical clinic center in Al Wakrah which has commenced its operations during February 2019. The operation of medical clinic in Wakra was discontinued with effect from 30 April 2024.

The interim condensed financial statements of the Company for the nine months ended 30 September 2024 were authorized for issue in accordance with a resolution of the Board of Directors on 23 October 2024.

### 2 BASIS OF PREPARATION

The interim condensed financial statements of the Company are prepared in accordance with International Accounting Standard (“IAS”) 34, Interim Financial Reporting. The financial statements are presented in Qatari Riyals (“QR”), which is the Company’s functional and presentation currency. The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the annual financial statements of the Company for the year ended 31 December 2023. In addition, results for the nine month period ended 30 September 2024 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2024.

### 3 USES OF JUDGEMENTS AND ESTIMATES

In preparing these interim condensed financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those described in the annual financial statements as at and for the year ended 31 December 2023.

### 4 PROPERTY AND EQUIPMENTS

	<b>30 September 2024 (Unaudited) QR</b>	<b>31 December 2023 (Audited) QR</b>
Net book value at the beginning of the period /year	<b>1,048,647,205</b>	1,032,712,543
Additions	<b>42,056,168</b>	63,552,075
Revaluation	-	(21,550,911)
Discontinued operations (Note 9 (i))	<b>(36,242,212)</b>	-
Depreciation charge for the period/year	<b>(19,453,373)</b>	(26,066,502)
Net book value at end of the period/year	<b>1,035,007,788</b>	1,048,647,205

## Medicare Group Q.P.S.C.

### NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2024

#### 5 ACCOUNTS RECEIVABLE AND PREPAYMENTS

	<i>30 September 2024 (Unaudited) QR</i>	<i>31 December 2023 (Audited) QR</i>
Trade receivables	157,107,490	155,712,751
Advances to suppliers	27,825,260	24,391,860
Staff receivables	12,518,210	10,225,659
Prepaid expenses	5,655,762	3,901,971
Refundable deposits	1,697,600	2,206,100
Others	2,209,358	878,944
	<b>207,013,680</b>	<b>197,317,285</b>
Provision for expected credit losses on trade receivables	<b>(76,435,439)</b>	<b>(76,435,439)</b>
	<b>130,578,241</b>	<b>120,881,846</b>

#### 6 CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise of the following:

	<i>30 September 2024 (Unaudited) QR</i>	<i>31 December 2023 (Audited) QR</i>
Cash in hand	504,223	412,333
Cash at bank	19,914,578	12,087,304
Cash at bank - short-term deposits	78,000,000	-
	<b>98,418,801</b>	<b>12,499,637</b>
Short term deposits with maturity of more than 90 days	<b>(78,000,000)</b>	-
Cash on hand and at bank attributable to discontinued operations( Note 9)	<b>115,238</b>	-
	<b>20,534,039</b>	<b>12,499,637</b>

# Medicare Group Q.P.S.C.

## NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS

At 30 September 2024

### 7 OPERATING COSTS

	<i>For the nine-month period ended 30 September</i>	
	<i>2024</i>	<i>2023</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>QR</i>	<i>QR</i>
Staff costs	124,857,610	120,997,072
Medication and surgical costs	68,995,486	64,206,071
Doctors' charges	28,104,312	26,114,081
Depreciation of medical equipment	6,836,540	6,234,532
Utilities	3,113,224	2,593,211
Food costs	2,627,825	2,428,195
Fuel costs	1,139,803	1,060,678
Provision for obsolete inventories	198,892	-
	<b>235,873,692</b>	<b>223,633,840</b>

### 8 GENERAL AND ADMINISTRATIVE EXPENSES

	<i>For the nine-month period ended 30 September</i>	
	<i>2024</i>	<i>2023</i>
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>QR</i>	<i>QR</i>
Staff costs	45,608,669	40,271,414
Maintenance and repairs	5,651,159	6,930,588
Outsourced staff costs	4,326,763	4,285,466
IT development	3,856,792	3,083,114
Security and cleaning	3,728,905	2,687,910
Insurance	2,658,446	2,650,982
Advertisement and promotions	1,979,538	1,212,458
Telephone and fax	1,384,572	1,758,627
Legal and professional fees	1,153,669	1,555,471
Board of Directors' remuneration	1,103,812	1,765,075
Bank charges	885,561	771,029
Printing and stationery	588,919	479,805
Government expenses	430,574	326,914
Others	1,266,793	1,210,545
	<b>74,624,172</b>	<b>68,989,398</b>



**9 DISCONTINUED OPERATIONS**

On 30 April 2024, the Company ceased the operations of Wakra Clinic and was classified as asset held for sale and discontinued operations. As a result, revenues and expenses, and gains and losses relating to the discontinuation of this operation have been removed from the results of continuing operations and are presented as a single line item on the face of the interim condensed statement of profit or loss and other comprehensive income and comparative information has been reclassified to be consistent with this presentation.

The results of Wakra Clinic for the period are presented below:

	<i>30 Sep 2024</i> <i>(Unaudited)</i> <i>QR</i>	<i>30 Sep 2023</i> <i>(Unaudited)</i> <i>QR</i>
Operating income	34,198	299,752
Operating costs	<u>(750,930)</u>	<u>(2,850,994)</u>
<b>Gross loss</b>	<u>(716,732)</u>	<u>(2,551,242)</u>
General and administrative expenses	(451,493)	(863,559)
Depreciation of property and equipment	(935,757)	(2,120,189)
Amortisation of right-of-use assets	(783,168)	(1,762,128)
Finance costs	<u>(535,258)</u>	<u>(1,259,882)</u>
<b>Loss for the period from discontinued operations</b>	<u>(3,422,408)</u>	<u>(8,557,000)</u>
<b>Discontinued operations:</b>		
Impairment of non-financial assets (i)	(36,242,212)	-
Gain on termination of lease (ii)	<u>5,568,712</u>	<u>-</u>
<b>Loss for the period</b>	<u>(34,095,908)</u>	<u>(8,557,000)</u>
	<i>30 Sep 2024</i> <i>(Unaudited)</i> <i>QR</i>	
<b>Assets</b>		
Trade receivables	34,427	
Deposits and other receivables	<u>10,800</u>	
	<u>45,227</u>	
Cash on hand	3,000	
Cash at bank	<u>112,238</u>	
	<u>115,238</u>	
<b>Total assets</b>	<u>160,465</u>	

*i. Impairment of non financial assets*

Immediately before the classification of Wakra Clinic as discontinued operations, the recoverable amount was estimated for leasehold improvements under property and equipment and impairment loss were identified. Following the classification, a write-down of QR 36,242,212 was recognised on 1 May 2024 to reduce the carrying amount of the assets in the disposal group to their fair value less costs to sell. This was recognised in discontinued operations in the interim condensed statement of profit or loss and other comprehensive income.

*ii. Gain on termination of lease*

Immediately after the classification of Wakra Clinic as discontinued operations, the lease contract for the Clinic was terminated and entire amount of QR 34,459,383 of right of use asset and lease liability of QR 40,028,095 were derecognised. Accordingly, a gain of termination of lease of QR 5,568,712 was recognized.